Leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment.

MLA

Mestre-Ferrandiz, Jorge, et al. “Leveraging the Holistic Benefits of Biosimilars in Europe – Part 2: How Payers Can Safeguard the Future of a Healthy Biosimilar Market Environment.” Expert Review of Pharmacoeconomics & Outcomes Research, vol. 24, no. 4, Apr. 2024, pp. 509–19. EBSCOhost, https://doi.org/10.1080/14737167.2024.2310684.

APA

Mestre-Ferrandiz, J., Czech, M., Smolen, J. S., Cornes, P., Aapro, M. S., Danese, S., Deitch, S., Tyldsley, H., Foster, W., Shah, P., Latymer, M., & Vulto, A. G. (2024). Leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment. Expert Review of Pharmacoeconomics & Outcomes Research, 24(4), 509–519. https://doi.org/10.1080/14737167.2024.2310684

Chicago

Mestre-Ferrandiz, Jorge, Marcin Czech, Josef S. Smolen, Paul Cornes, Matti S. Aapro, Silvio Danese, Stephen Deitch, et al. 2024. “Leveraging the Holistic Benefits of Biosimilars in Europe – Part 2: How Payers Can Safeguard the Future of a Healthy Biosimilar Market Environment.” Expert Review of Pharmacoeconomics & Outcomes Research 24 (4): 509–19. doi:10.1080/14737167.2024.2310684.